Literature DB >> 2204510

Serum aminoterminal type III procollagen peptide in early rheumatoid arthritis: relation to disease activity and progression of joint damage.

K Eberhardt1, L Thorbjorn Jensen, K Horslev-Petersen, H Pettersson, I Lorenzen, F Wollheim.   

Abstract

Serum levels of the aminoterminal type III procollagen peptide (S-PIIINP) have been used as markers of proliferative inflammation in rheumatoid arthritis (RA) and a prognostic significance has been suggested. To test this further we have measured S-PIIINP longitudinally for 2 years in 66 patients with definite RA and a disease duration of less than 2 years, and related the levels to clinical, biochemical, and radiographic findings. In this patient group the correlations between S-PIIINP and ESR and CRP, respectively, were higher than those obtained between S-PIIINP and articular indices, and markedly higher than in patients with RA of longer duration. Patients with normal mean levels of S-PIIINP during the study period had a significantly slower rate of radiographic progression than patients with elevated mean levels of S-PIIINP. ESR yielded in general higher correlations with the joint damage process than did S-PIIINP. The correlations between S-PIIINP and the joint damage scores increased with time. A multiple regression analysis showed that ESR explained most of the variance in joint damage progression over 2 years, but S-PIIINP added independent information. About one third of the variance could be explained by the two variables.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204510

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  4 in total

1.  Synovial fluid and serum concentrations of aminoterminal propeptide of type III procollagen in healthy volunteers and patients with joint disease.

Authors:  M Sharif; E George; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

2.  Serum N terminal procollagen III fragment: a predictive marker of joint destruction in rheumatoid arthritis?

Authors:  J G Tebib; P Viguier; E Noel; F Colson; Y Barbier; M Bouvier
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

3.  Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community.

Authors:  Thomas J Wang; Martin G Larson; Emelia J Benjamin; Deborah A Siwik; Radwan Safa; Chao-Yu Guo; Diane Corey; Johan Sundstrom; Douglas B Sawyer; Wilson S Colucci; Ramachandran S Vasan
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

4.  Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma.

Authors:  C Blomqvist; L Risteli; J Risteli; P Virkkunen; S Sarna; I Elomaa
Journal:  Br J Cancer       Date:  1996-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.